Mizuho Begins Coverage on EIKN (NASDAQ:EIKN)

Mizuho assumed coverage on shares of EIKN (NASDAQ:EIKN) in a research note issued to investors on Monday,Benzinga reports. The firm set an “outperform” rating and a $26.00 price target on the stock. Mizuho’s price objective suggests a potential upside of 88.68% from the company’s previous close.

A number of other equities analysts have also recently commented on the stock. Bank of America began coverage on shares of EIKN in a research note on Monday. They issued a “buy” rating and a $34.00 price target for the company. Wall Street Zen upgraded shares of EIKN to a “hold” rating in a research report on Monday, February 16th. Finally, Wedbush initiated coverage on EIKN in a research report on Thursday. They set an “underperform” rating and a $7.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $24.75.

EIKN Trading Up 1.0%

Shares of NASDAQ EIKN opened at $13.78 on Monday. EIKN has a 12 month low of $13.28 and a 12 month high of $17.40.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.